A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2017
At a glance
- Drugs NUC 1031 (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors NuCana
- 15 Nov 2017 According to a NuCana media release, first patients have been enrolled in both the US and the UK. NuCana expects to announce interim data from this study in 2018.
- 18 Sep 2017 Last checked against ClinicalTrials.gov record
- 13 Sep 2017 Status changed from not yet recruiting to recruiting.